Melanoma Clinical Trial

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Summary

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1
At least 1 lesion accessible for biopsy
Eastern Cooperative Oncology Group Performance Status of 0 or 1

Exclusion Criteria:

Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)
Participants with active, known or suspected autoimmune disease
Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)
Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy

Other protocol defined inclusion/exclusion criteria could apply

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

372

Study ID:

NCT03400332

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 78 Locations for this study

See Locations Near You

Highlands Oncology Group-Research Department
Springdale Arkansas, 72762, United States More Info
Joseph Beck, Site 0059
Contact
479-872-8130
LAC + USC Medical Center
Los Angeles California, 90033, United States More Info
Gino In, Site 0099
Contact
323-865-3900
University Of Colorado
Aurora Colorado, 80045, United States
Local Institution - 0007
Lakewood Colorado, 80228, United States
Local Institution
Miami Beach Florida, 33140, United States
Winship Cancer Institute of Emory University
Atlanta Georgia, 30322, United States More Info
Melinda Yushak, Site 0087
Contact
404-778-1900
Northside Hospital
Atlanta Georgia, 30342, United States More Info
Harpaul Gill, Site 0100
Contact
770-205-5292
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Marietta Georgia, 30060, United States More Info
Steven McCune, Site 0101
Contact
770-281-5100
Local Institution - 0012
Columbia Maryland, 21044, United States
Sidney kimmel comprehensive cancer center at johns hopkins
Lutherville Maryland, 21093, United States More Info
William Sharfman, Site 0003
Contact
410-583-2970
Dana Farber Cancer Institute.
Boston Massachusetts, 02215, United States More Info
F. Stephen Hodi, Site 0060
Contact
617-632-7415
University Of Michigan Health System
Ann Arbor Michigan, 48109, United States
Nebraska Cancer Specialists
Omaha Nebraska, 68130, United States More Info
Ralph Hauke, Site 0076
Contact
402-334-4773
Comprehensive Cancer Centers Of Nevada
Las Vegas Nevada, 89169, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Martin Gutierrez, Site 0005
Contact
551-996-5863
Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08903, United States
Icahn School Of Medicine At Mount Sinai
New York New York, 10029, United States More Info
Thomas Marron, Site 0025
Contact
703-609-9912
Columbia University Medical Center (Cumc)
New York New York, 10032, United States More Info
Brian Henick, Site 0002
Contact
646-317-4193
Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States More Info
Susanna Ulahannan, Site 0028
Contact
580-767-1300
Local Institution - 0017
Eugene Oregon, 97401, United States
Local Institution
Philadelphia Pennsylvania, 19111, United States
UPMC Cancer Center
Pittsburgh Pennsylvania, 15213, United States More Info
Diwakar Davar, Site 0001
Contact
000-000-0000
Local Institution - 0009
Greenville South Carolina, 29615, United States
Local Institution - 0011
Austin Texas, 78705, United States
Local Institution - 0010
Dallas Texas, 75246, United States
Texas Oncology-Fort Worth 12th Ave
Fort Worth Texas, 76104, United States
Local Institution - 0018
Houston Texas, 77030, United States
Local Institution - 0006
San Antonio Texas, 78240, United States
Local Institution - 0013
Tyler Texas, 75702, United States
Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States More Info
Siwen Hu-Lieskovan, Site 0058
Contact
323-309-6688
Local Institution - 0015
Fairfax Virginia, 22031, United States
Local Institution - 0008
Norfolk Virginia, 23502, United States
VCU Health Adult Outpatient Pavillion
Richmond Virginia, 23219, United States More Info
Andrew Poklepovic, Site 0065
Contact
804-628-2321
Local Institution - 0088
Wollstonecraft New South Wales, 2065, Australia More Info
Site 0088
Contact
Local Institution - 0096
Adelaide South Australia, 5000, Australia More Info
Site 0096
Contact
Local Institution - 0090
Melbourne Victoria, 3000, Australia More Info
Site 0090
Contact
Local Institution - 0095
Melbourne Victoria, 3004, Australia More Info
Site 0095
Contact
Local Institution - 0097
Perth Western Australia, 6009, Australia More Info
Site 0097
Contact
Local Institution - 0091
Ballarat Central , VIC 3, Australia More Info
Site 0091
Contact
Local Institution - 0037
Bruxelles , 1200, Belgium More Info
Site 0037
Contact
Local Institution - 0036
Gent , 9000, Belgium More Info
Site 0036
Contact
Local Institution - 0082
Kortrijk , 8500, Belgium More Info
Site 0082
Contact
Local Institution - 0030
Edmonton Alberta, T6G 1, Canada More Info
Site 0030
Contact
Local Institution - 0029
Vancouver British Columbia, V5Z 4, Canada More Info
Site 0029
Contact
Local Institution - 0078
Victoria British Columbia, V8R 6, Canada More Info
Site 0078
Contact
Local Institution - 0020
Toronto Ontario, M5G 1, Canada
Local Institution - 0055
Toronto Ontario, M5G 2, Canada More Info
Site 0055
Contact
Local Institution - 0056
Montréal , H2X 0, Canada More Info
Site 0056
Contact
Local Institution - 0067
Marseille Bouches-du-Rhône, 13385, France More Info
Site 0067
Contact
Local Institution - 0085
Nantes , 44000, France More Info
Site 0085
Contact
Local Institution - 0068
Paris , 75010, France More Info
Site 0068
Contact
Local Institution - 0102
Toulouse , 31059, France More Info
Site 0102
Contact
Local Institution - 0069
Villejuif , 94800, France More Info
Site 0069
Contact
Local Institution - 0052
Mainz Rheinland-Pfalz, 55131, Germany More Info
Site 0052
Contact
Local Institution - 0034
Berlin , 12200, Germany More Info
Site 0034
Contact
Local Institution
Gerlingen , 70839, Germany
Local Institution
Hamburg , 20246, Germany
Local Institution - 0053
Hamburg , 20251, Germany More Info
Site 0053
Contact
Local Institution
Mainz , 55131, Germany
Local Institution - 0054
Tübingen , 72076, Germany More Info
Site 0054
Contact
IRST Meldola
Forlì , 47014, Italy More Info
Angelo Delmonte, Site 0043
Contact
+393487469100
Ospedale San Raffaele
Milano , 20132, Italy More Info
Gianluca Del Conte, Site 0042
Contact
+390226436523
Istituto Nazionale Tumori Fondazione Pascale
Napoli , 80131, Italy More Info
Paolo Ascierto, Site 0027
Contact
390815903431
Irccs Istituto Clinico Humanitas
Rozzano-milano , 20089, Italy More Info
Matteo Simonelli, Site 0026
Contact
+390282244559
Local Institution - 0071
Krakow , 31-11, Poland More Info
Site 0071
Contact
Local Institution - 0077
Warszawa , 02-78, Poland More Info
Site 0077
Contact
Local Institution - 0045
Madrid , 28034, Spain More Info
Site 0045
Contact
Local Institution - 0022
Madrid , 28040, Spain More Info
Site 0022
Contact
Local Institution - 0023
Madrid , 28050, Spain More Info
Site 0023
Contact
Local Institution - 0044
Malaga , 29010, Spain More Info
Site 0044
Contact
Local Institution - 0021
Pamplona , 31008, Spain More Info
Site 0021
Contact
Local Institution - 0047
Santiago de Compostela , 15706, Spain More Info
Site 0047
Contact
Local Institution - 0040
Lausanne , 1011, Switzerland More Info
Site 0040
Contact
Local Institution - 0041
St.Gallen , 9007, Switzerland More Info
Site 0041
Contact
Local Institution - 0039
Zuerich , 8091, Switzerland More Info
Site 0039
Contact
Local Institution - 0024
Manchester Greater Manchester, M20 4, United Kingdom More Info
Site 0024
Contact
Local Institution - 0083
Glasgow Lanarkshire, G12 0, United Kingdom More Info
Site 0083
Contact
Local Institution - 0019
Birmingham West Midlands, B15 2, United Kingdom More Info
Site 0019
Contact
Local Institution - 0084
Newcastle upon Tyne , NE7 7, United Kingdom More Info
Site 0084
Contact

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

372

Study ID:

NCT03400332

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.